Provided by Tiger Fintech (Singapore) Pte. Ltd.

Estrella Immunopharma

1.00
+0.04004.17%
Post-market: 1.000.00000.00%18:09 EDT
Volume:53.49K
Turnover:52.04K
Market Cap:36.17M
PE:-4.12
High:1.11
Open:0.9800
Low:0.9452
Close:0.9600
Loading ...
Mar 07, 2024

Major Issues Report

Form 8-K - Current report
Feb 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 02, 2024

Major Issues Report

Form 8-K - Current report
Jan 31, 2024

Major Issues Report

Form 8-K - Current report
Dec 28, 2023

Correspondence

Form CORRESP - Correspondence
Dec 18, 2023

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Dec 16, 2023

Correspondence

Form CORRESP - Correspondence
Nov 21, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 14, 2023

Major Issues Report

Form 8-K/A - Current report: [Amend]
Nov 14, 2023

Correspondence

Form CORRESP - Correspondence
Nov 13, 2023

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Oct 30, 2023

Beneficial Ownership Change

Form SC 13D - General statement of acquisition of beneficial ownership
Oct 11, 2023

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Oct 05, 2023

Delisting

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Oct 05, 2023

Major Issues Report

Form 8-K - Current report
Sep 20, 2023

Major Issues Report

Form 8-K - Current report
Sep 20, 2023

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Sep 18, 2023

Major Issues Report

Form 8-K - Current report
Sep 18, 2023

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Aug 18, 2023

Major Issues Report

Form 8-K - Current report